Evidence map›Paper›PMID 37894806›Full record

ReviewInternational journal of molecular sciences2023

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.

Peter Valent, Cem Akin, Michel Arock, Karoline V Gleixner, Hildegard Greinix, Olivier Hermine, Hans-Peter Horny, Daniel Ivanov, Alberto Orfao, Werner Rabitsch and 5 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 5 countries.

Peter ValentDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-0456-5095
Cem AkinDivision of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, MI 48106, USA.
Michel ArockDepartment of Hematological Biology, Pitié-Salpêtrière Hospital, Sorbonne University, 75013 Paris, France.ORCID 0000-0002-3990-4408
Karoline V GleixnerDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
Hildegard GreinixDivision of Hematology, Medical University of Graz, 8010 Graz, Austria.
Olivier HermineService d'Hématologie, Imagine Institute Université de Paris, INSERM U1163, Centre National de Référence des Mastocytoses, Hôpital Necker, Assistance Publique Hôpitaux de Paris, 75015 Paris, France.
Hans-Peter HornyInstitute of Pathology, Ludwig-Maximilians University, 80539 Munich, Germany.
Daniel IvanovDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-1304-4224
Alberto OrfaoServicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC; CSIC/USAL) Instituto Biosanitario de Salamanca (IBSAL), CIBERONC and Department of Medicine, University of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0002-0007-7230
Werner RabitschDepartment of Internal Medicine I, Stem Cell Transplantation Unit, Medical University of Vienna, 1090 Vienna, Austria.
Andreas ReiterDepartment of Hematology and Oncology, University Hospital Mannheim, 68135 Mannheim, Germany.
Axel SchulenburgDepartment of Internal Medicine I, Stem Cell Transplantation Unit, Medical University of Vienna, 1090 Vienna, Austria.
Karl SotlarInstitute of Pathology, University Hospital Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.
Wolfgang R SperrDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
Celalettin UstunDepartment of Medicine, Division of Hematology, Oncology, and Cell Therapy, Coleman Foundation Blood and Marrow Transplant Center at Rush University Medical Center, Chicago, IL 60612, USA.
Medical University of Vienna · ATHeidelberg University · DEHôpital Necker-Enfants Malades · FRLudwig-Maximilians-Universität München · DEMedical University of Graz · ATParacelsus Medical University · ATRush University Medical Center · USSorbonne Université · FRUniversidad de Salamanca · ESUniversity of Michigan · US

Funding

Austrian Science Fund FWF DOC 59
6 · The paper itself

Abstract

Advanced systemic mastocytosis (SM) is a heterogeneous group of myeloid neoplasms characterized by an uncontrolled expansion of mast cells (MC) in one or more internal organs, SM-induced tissue damage, and poor prognosis. Advanced SM can be categorized into aggressive SM (ASM), MC leukemia (MCL), and SM with an associated hematologic neoplasm (SM-AHN). In a vast majority of all patients, neoplastic cells display a

Indexed as

MastocytosisMastocytosis, SystemicHumansMast CellsMutationProto-Oncogene Proteins c-kitQuality of LifeProto-Oncogene Proteins c-kitCAR-TCAR-therapyimmunotherapymast cell leukemiamastocytosisstem cell transplantation

Identifiers

PMID37894806
PMCPMC10607143
OpenAlexW4387569599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.